MA53898A - Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament - Google Patents

Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament

Info

Publication number
MA53898A
MA53898A MA053898A MA53898A MA53898A MA 53898 A MA53898 A MA 53898A MA 053898 A MA053898 A MA 053898A MA 53898 A MA53898 A MA 53898A MA 53898 A MA53898 A MA 53898A
Authority
MA
Morocco
Prior art keywords
pyrazin
ylmethyl
medicines
morpholine derivatives
morpholine
Prior art date
Application number
MA053898A
Other languages
English (en)
Other versions
MA53898B1 (fr
Inventor
Angelo Ceci
Cornelia Dorner-Ciossek
Riccardo Giovannini
Roland Pfau
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA53898A publication Critical patent/MA53898A/fr
Publication of MA53898B1 publication Critical patent/MA53898B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA53898A 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament MA53898B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament

Publications (2)

Publication Number Publication Date
MA53898A true MA53898A (fr) 2022-01-26
MA53898B1 MA53898B1 (fr) 2023-03-31

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53898A MA53898B1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament

Country Status (38)

Country Link
US (3) US11166958B2 (fr)
EP (1) EP3867244B1 (fr)
JP (1) JP7093468B2 (fr)
KR (1) KR102840105B1 (fr)
CN (1) CN112888685B (fr)
AR (1) AR116711A1 (fr)
AU (1) AU2019362330B2 (fr)
BR (1) BR112021004993A2 (fr)
CA (1) CA3113308A1 (fr)
CL (1) CL2021000858A1 (fr)
CO (1) CO2021004612A2 (fr)
CR (1) CR20210184A (fr)
DK (1) DK3867244T3 (fr)
DO (1) DOP2021000069A (fr)
EA (1) EA202191014A1 (fr)
EC (1) ECSP21027009A (fr)
ES (1) ES2940184T3 (fr)
FI (1) FI3867244T3 (fr)
HR (1) HRP20230249T1 (fr)
HU (1) HUE061891T2 (fr)
IL (1) IL282142B2 (fr)
JO (1) JOP20210075B1 (fr)
LT (1) LT3867244T (fr)
MA (1) MA53898B1 (fr)
MX (1) MX2021004418A (fr)
MY (1) MY205127A (fr)
NZ (1) NZ773672A (fr)
PE (1) PE20211278A1 (fr)
PH (1) PH12021550834A1 (fr)
PL (1) PL3867244T3 (fr)
PT (1) PT3867244T (fr)
RS (1) RS63988B1 (fr)
SA (1) SA521421756B1 (fr)
SG (1) SG11202103806VA (fr)
SI (1) SI3867244T1 (fr)
TW (1) TWI828779B (fr)
UA (1) UA128408C2 (fr)
WO (1) WO2020079039A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245136A1 (fr) * 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Dérivés de purine, utilisés en tant que modulateurs négatifs de nr2b et leur utilisation en tant que médicament, en particulier pour le traitement de troubles dépressifs
WO2025233259A1 (fr) 2024-05-07 2025-11-13 Boehringer Ingelheim International Gmbh Composé destiné à être utilisé dans le traitement de la dépression, d'un trouble obsessionnel compulsif, d'un trouble de stress post-traumatique et/ou d'un trouble de la personnalité borderline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
EP1390034A4 (fr) 2001-04-03 2005-07-13 Merck & Co Inc Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
KR100890676B1 (ko) * 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
US7855201B2 (en) * 2005-12-06 2010-12-21 Merck Sharp & Dohme. Corp. Morpholine carboxamide prokineticin receptor antagonists
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (fr) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
MY168937A (en) 2012-10-18 2019-01-10 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
AU2015223049B2 (en) * 2014-02-27 2019-03-21 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
CA3001894A1 (fr) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Antagonistes selectifs de nr2b

Also Published As

Publication number Publication date
IL282142B1 (en) 2023-12-01
ES2940184T3 (es) 2023-05-04
SG11202103806VA (en) 2021-05-28
EP3867244A1 (fr) 2021-08-25
PL3867244T3 (pl) 2023-05-22
AU2019362330A1 (en) 2021-04-08
LT3867244T (lt) 2023-03-10
CL2021000858A1 (es) 2021-10-01
CO2021004612A2 (es) 2021-04-30
KR102840105B1 (ko) 2025-07-31
RS63988B1 (sr) 2023-03-31
JP2022505080A (ja) 2022-01-14
DK3867244T3 (da) 2023-05-01
AU2019362330B2 (en) 2024-03-28
US20210393644A1 (en) 2021-12-23
HUE061891T2 (hu) 2023-09-28
EA202191014A1 (ru) 2021-11-09
CA3113308A1 (fr) 2020-04-23
US20250345341A1 (en) 2025-11-13
US20200121691A1 (en) 2020-04-23
CR20210184A (es) 2021-05-26
PE20211278A1 (es) 2021-07-19
JP7093468B2 (ja) 2022-06-29
NZ773672A (en) 2024-12-20
BR112021004993A2 (pt) 2021-06-08
IL282142B2 (en) 2024-04-01
FI3867244T3 (fi) 2023-03-20
TWI828779B (zh) 2024-01-11
CN112888685B (zh) 2023-09-22
SI3867244T1 (sl) 2023-04-28
ECSP21027009A (es) 2021-05-31
MA53898B1 (fr) 2023-03-31
SA521421756B1 (ar) 2023-02-12
DOP2021000069A (es) 2021-05-31
HRP20230249T1 (hr) 2023-04-14
KR20210079325A (ko) 2021-06-29
JOP20210075A1 (ar) 2023-01-30
PT3867244T (pt) 2023-02-22
MX2021004418A (es) 2021-07-06
IL282142A (en) 2021-05-31
EP3867244B1 (fr) 2023-01-18
JOP20210075B1 (ar) 2024-12-22
PH12021550834A1 (en) 2021-10-04
MY205127A (en) 2024-10-03
UA128408C2 (uk) 2024-07-03
WO2020079039A1 (fr) 2020-04-23
US11166958B2 (en) 2021-11-09
CN112888685A (zh) 2021-06-01
TW202031262A (zh) 2020-09-01
AR116711A1 (es) 2021-06-02

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3778608A4 (fr) Dérivés de carbamoylpyridone polycycliques, compositions pharmaceutiques et utilisation de ceux-ci
MA52421A (fr) Composés pharmaceutiques
EP3732185A4 (fr) Conjugués et préparation et utilisation associées
MA44075A (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EP3663286A4 (fr) Photosensibilisateur, dérivés et application correspondante
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
EP3856292C0 (fr) Safety syringe
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
EP3795123C0 (fr) Systèmes de pesage médicaux
EP3781576C0 (fr) Dérivés d'acide boronique et leurs utilisations thérapeutiques
EP3541385A4 (fr) Formulations pharmaceutiques
MA56183A (fr) Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
EP3845528A4 (fr) Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées
EP3334719A4 (fr) Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
EP3802495A4 (fr) Dérivés hétérocycliques et leur utilisation
EP3686204A4 (fr) Dérivés de thiénodiazépine et leur application
EP3715344A4 (fr) Dérivés de 1,4-benzodiazépine et leur utilisation
EP3328368A4 (fr) Composés et composition pharmaceutique associée au système d'ubiquitination-protéasome
IL282157A (en) Compounds and therapeutic uses thereof
MA47516A (fr) Composition pharmaceutique
MA40524A (fr) Dérivés d'adrénomédulline stabilisés et leur utilisation
EP3590515A4 (fr) Produit médicamenteux
PL3480200T3 (pl) Aktywna optycznie pochodna piranochromenylofenolu i kompozycja farmaceutyczna ją zawierająca